This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1998;279:645.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved a tobramycin solution product for inhalation (TOBI, PathoGenesis Corporation, Seattle, Wash) for use in the treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis who are at least 6 years of age. Two double-blind, randomized, placebo-controlled, 24-week clinical studies demonstrated effectiveness of tobramycin as administered in the new formulation. A total of 258 treated patients showed significant improvement in pulmonary function and significant decrease in the number of hospitalized days compared with placebo controls. In 1 study, percent predicted FEV₁ (forced expiratory volume in 1 second) increased relatively about 7% on average among treated patients compared with an average decrease of 1% among patients in the placebo group. TOBI was administered twice a day in a regimen of 28 days on and 28 days off the drug.

Tobramycin, first approved in 1975 in injection form, was reformulated for inhalation to reduce adverse effects associated with . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?